Огляд тенденцій у сфері охорони здоров’я та біологічних наук. Картина змінюється (англійською мовою)

The Ukrainian phar­maceutical market has traditionally been considered one of the most developed in the entire post-Soviet space. This positive assessment is based on a number of factors including the existence of large pharmaceutical production facilities in Ukraine, a good educational background and, as a consequence, qualified person­nel involved in the pharmaceutical industry. The size of the Ukrainian pharmaceutical market as of 2013 exceeded USD 3.2 billion. However, the situation on the market is undergoing changes.

Proposed medical reforms, recent­ly announced by the government of Ukraine, have caused a storm of indignation among nation­al pharmaceutical manufactur­ers. First of all, this concerns the re-registration of pharmaceutical products previously authorized by the Ukrainian regulator in accord­ance with European requirements. Such “know-how” is justified by the Ministry of Health of Ukraine (MHU) by the need to harmonize the two systems – Ukrainian and European. This argument has a dual nature. On the one hand, indeed, Ukraine has signed an Association Agreement with the EU and har­monization is a part of the coun­try’s planned European integration. On the other hand, the association agreement does not provide for a rigid period for harmonization, and in the absence of a clear understand­ing of Ukraine’s future EU member­ship perspectives, it is quite difficult to see the above-mentioned “know­how” as a priority goal.

The MHU’s argument regard­ing the need for the re-registration of pharmaceutical products for national manufacturer is also quite questionable. Following the MHU’s logic, this will allow Ukrainian companies to enter Western mar­kets without impediment and thereby increase the export of their products. This argument does not hold water as it directly concerns the strategic planning of pharmaceutical companies. Most Ukrainian compa­nies in this sector do not strive to enter highly compet­itive Western markets.

Nevertheless, we have what we have. The need to re-register pharmaceutical products significantly weak­ens the position of national pharmaceutical manufac­turers in the pharmaceutical market. At the same time, the introduction of so-called simplified registration procedures for imported pharmaceutical products cre­ates favourable conditions for the expansion of foreign manufacturers of pharmaceutical products in Ukraine. This simplified procedure entitles manufacturers of the pharmaceutical products certified in other countries to import and sell their pharmaceutical products in Ukraine. Within the simplified procedure, registration data is verified with the country of origin of the pharma­ceutical product. Prior to the introduction of this sim­plified procedure, the process of Ukrainian registration took approximately two years.

These changes create permanent confrontation between national pharmaceutical manufacturers on the one hand and the MHU and foreign producers on the other. Inability to find a compromise in this con­frontation leads to serious weakening of the pharma­ceutical market.

The current situation on the market of pharmaceu­tical products in Ukraine creates certain economic and social effects. In particular, the increase in imported pharmaceutical products to Ukraine negatively affects the country’s economy, and creates grounds for various antitrust investigations regarding fair competition in the pharmaceutical market.

At the same time, it is assumed that the introduc­tion of a simplified procedure for the import and sale of pharmaceutical products on the territory of Ukraine will significantly reduce the prices for imported pharma­ceutical products and will allow foreign pharmaceutical products to enter the Ukrainian market. This, in its turn, can positively affect the health of Ukrainian citizens.

Moreover, the current situation in the pharmaceuti­cal market creates fertile ground for the establishment of strategic alliances of foreign and national pharma­ceutical manufacturers. In other words, the weakening of national manufacturers may result in mergers of national pharmaceutical manufacturers with their for­eign competitors. This, in turn, can reduce the import of pharmaceutical products into the country, and increase the investment component in the structure of Ukraine’s GDP.


Подібні публікації

26 Січня 2023


Гра з тінню: чим небезпечні нелегальні казино та звідки вони беруться?
24 Січня 2023


Хто за все заплатить: як рітейлу фіксувати збитки та на які варіанти відшкодування можна розраховувати
19 Січня 2023


Закон № 2805-ix: аналіз Sayenko Kharenko
Cookies повідомлення

Ми використовуємо дані cookie, щоб аналізувати поведінку відвідувачів
нашого сайту та покращувати його. Використовуючи наш сайт, ви даєте згоду на дані cookie відповідно до нашої Cookie Policy.